Reality Check On UK Production Capacity For COVID-19 Treatments

Debate Shifts From Treatments To Scalability, Manufacturing Capacity, And Delivery

In the first of a two-part series of articles on the UK COVID-19 Therapeutics Task Force, the Pink Sheet reports on how task force members are examining the role of therapeutics in tackling the pandemic and why the UK’s manufacturing capability needs to be strengthened so it can meet future demand. The second article will cover the work of the task force and how it is structured to identify and advance promising coronavirus treatments. 

Pill Production
Manufacturing capacity is under the spotlight • Source: Shutterstock

Alongside the frenetic development of candidate vaccines for COVID-19, many dozens of therapeutic projects are under way in the UK to assess the use of new and repurposed medicines. One of them, the Recovery trial, has already revealed the potential of dexamethasone as a treatment for hospitalized patients.

Just showing that a promising treatment works will not be enough, though. Drug developers will need to demonstrate that they...

Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

More from United Kingdom

More from Europe